A case for protein-level and site-level specificity in glycoproteomic studies of disease

Katherine N. Schumacher, Eric D Dodds

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Abnormal glycosylation of proteins is known to be either resultant or causative of a variety of diseases. This makes glycoproteins appealing targets as potential biomarkers and focal points of molecular studies on the development and progression of human ailment. To date, a majority of efforts in disease glycoproteomics have tended to center on either determining the concentration of a given glycoprotein, or on profiling the total population of glycans released from a mixture of glycoproteins. While these approaches have demonstrated some diagnostic potential, they are inherently insensitive to the fine molecular detail which distinguishes unique and possibly disease relevant glycoforms of specific proteins. As a consequence, such analyses can be of limited sensitivity, specificity, and accuracy because they do not comprehensively consider the glycosylation status of any particular glycoprotein, or of any particular glycosylation site. Therefore, significant opportunities exist to improve glycoproteomic inquiry into disease by engaging in these studies at the level of individual glycoproteins and their exact loci of glycosylation. In this concise review, the rationale for glycoprotein and glycosylation site specificity is developed in the context of human disease glycoproteomics with an emphasis on N-glycosylation. Recent examples highlighting disease-related perturbations in glycosylation will be presented, including those involving alterations in the overall glycosylation of a specific protein, alterations in the occupancy of a given glycosylation site, and alterations in the compositional heterogeneity of glycans occurring at a given glycosylation site. Each will be discussed with particular emphasis on how protein-specific and site-specific approaches can contribute to improved discrimination between glycoproteomes and glycoproteins associated with healthy and unhealthy states.

Original languageEnglish (US)
Pages (from-to)1-9
Number of pages9
JournalGlycoconjugate Journal
DOIs
StateAccepted/In press - Mar 23 2016

Fingerprint

Glycosylation
Glycoproteins
Proteins
Polysaccharides
Human Development
Biomarkers

Keywords

  • Disease
  • Glycomics
  • Glycoproteomics
  • Glycosylation site occupancy
  • Microheterogeneity
  • Protein glycoforms
  • Released glycan profiling
  • Site-specific glycosylation

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Molecular Biology

Cite this

A case for protein-level and site-level specificity in glycoproteomic studies of disease. / Schumacher, Katherine N.; Dodds, Eric D.

In: Glycoconjugate Journal, 23.03.2016, p. 1-9.

Research output: Contribution to journalArticle

@article{9f7eb80a54614c4ea3115053ab21617e,
title = "A case for protein-level and site-level specificity in glycoproteomic studies of disease",
abstract = "Abnormal glycosylation of proteins is known to be either resultant or causative of a variety of diseases. This makes glycoproteins appealing targets as potential biomarkers and focal points of molecular studies on the development and progression of human ailment. To date, a majority of efforts in disease glycoproteomics have tended to center on either determining the concentration of a given glycoprotein, or on profiling the total population of glycans released from a mixture of glycoproteins. While these approaches have demonstrated some diagnostic potential, they are inherently insensitive to the fine molecular detail which distinguishes unique and possibly disease relevant glycoforms of specific proteins. As a consequence, such analyses can be of limited sensitivity, specificity, and accuracy because they do not comprehensively consider the glycosylation status of any particular glycoprotein, or of any particular glycosylation site. Therefore, significant opportunities exist to improve glycoproteomic inquiry into disease by engaging in these studies at the level of individual glycoproteins and their exact loci of glycosylation. In this concise review, the rationale for glycoprotein and glycosylation site specificity is developed in the context of human disease glycoproteomics with an emphasis on N-glycosylation. Recent examples highlighting disease-related perturbations in glycosylation will be presented, including those involving alterations in the overall glycosylation of a specific protein, alterations in the occupancy of a given glycosylation site, and alterations in the compositional heterogeneity of glycans occurring at a given glycosylation site. Each will be discussed with particular emphasis on how protein-specific and site-specific approaches can contribute to improved discrimination between glycoproteomes and glycoproteins associated with healthy and unhealthy states.",
keywords = "Disease, Glycomics, Glycoproteomics, Glycosylation site occupancy, Microheterogeneity, Protein glycoforms, Released glycan profiling, Site-specific glycosylation",
author = "Schumacher, {Katherine N.} and Dodds, {Eric D}",
year = "2016",
month = "3",
day = "23",
doi = "10.1007/s10719-016-9663-5",
language = "English (US)",
pages = "1--9",
journal = "Glycoconjugate Journal",
issn = "0282-0080",
publisher = "Springer Netherlands",

}

TY - JOUR

T1 - A case for protein-level and site-level specificity in glycoproteomic studies of disease

AU - Schumacher, Katherine N.

AU - Dodds, Eric D

PY - 2016/3/23

Y1 - 2016/3/23

N2 - Abnormal glycosylation of proteins is known to be either resultant or causative of a variety of diseases. This makes glycoproteins appealing targets as potential biomarkers and focal points of molecular studies on the development and progression of human ailment. To date, a majority of efforts in disease glycoproteomics have tended to center on either determining the concentration of a given glycoprotein, or on profiling the total population of glycans released from a mixture of glycoproteins. While these approaches have demonstrated some diagnostic potential, they are inherently insensitive to the fine molecular detail which distinguishes unique and possibly disease relevant glycoforms of specific proteins. As a consequence, such analyses can be of limited sensitivity, specificity, and accuracy because they do not comprehensively consider the glycosylation status of any particular glycoprotein, or of any particular glycosylation site. Therefore, significant opportunities exist to improve glycoproteomic inquiry into disease by engaging in these studies at the level of individual glycoproteins and their exact loci of glycosylation. In this concise review, the rationale for glycoprotein and glycosylation site specificity is developed in the context of human disease glycoproteomics with an emphasis on N-glycosylation. Recent examples highlighting disease-related perturbations in glycosylation will be presented, including those involving alterations in the overall glycosylation of a specific protein, alterations in the occupancy of a given glycosylation site, and alterations in the compositional heterogeneity of glycans occurring at a given glycosylation site. Each will be discussed with particular emphasis on how protein-specific and site-specific approaches can contribute to improved discrimination between glycoproteomes and glycoproteins associated with healthy and unhealthy states.

AB - Abnormal glycosylation of proteins is known to be either resultant or causative of a variety of diseases. This makes glycoproteins appealing targets as potential biomarkers and focal points of molecular studies on the development and progression of human ailment. To date, a majority of efforts in disease glycoproteomics have tended to center on either determining the concentration of a given glycoprotein, or on profiling the total population of glycans released from a mixture of glycoproteins. While these approaches have demonstrated some diagnostic potential, they are inherently insensitive to the fine molecular detail which distinguishes unique and possibly disease relevant glycoforms of specific proteins. As a consequence, such analyses can be of limited sensitivity, specificity, and accuracy because they do not comprehensively consider the glycosylation status of any particular glycoprotein, or of any particular glycosylation site. Therefore, significant opportunities exist to improve glycoproteomic inquiry into disease by engaging in these studies at the level of individual glycoproteins and their exact loci of glycosylation. In this concise review, the rationale for glycoprotein and glycosylation site specificity is developed in the context of human disease glycoproteomics with an emphasis on N-glycosylation. Recent examples highlighting disease-related perturbations in glycosylation will be presented, including those involving alterations in the overall glycosylation of a specific protein, alterations in the occupancy of a given glycosylation site, and alterations in the compositional heterogeneity of glycans occurring at a given glycosylation site. Each will be discussed with particular emphasis on how protein-specific and site-specific approaches can contribute to improved discrimination between glycoproteomes and glycoproteins associated with healthy and unhealthy states.

KW - Disease

KW - Glycomics

KW - Glycoproteomics

KW - Glycosylation site occupancy

KW - Microheterogeneity

KW - Protein glycoforms

KW - Released glycan profiling

KW - Site-specific glycosylation

UR - http://www.scopus.com/inward/record.url?scp=84961825249&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961825249&partnerID=8YFLogxK

U2 - 10.1007/s10719-016-9663-5

DO - 10.1007/s10719-016-9663-5

M3 - Article

SP - 1

EP - 9

JO - Glycoconjugate Journal

JF - Glycoconjugate Journal

SN - 0282-0080

ER -